Prediabetes drug development: a look at early human study findings and the sponsor’s planned follow‑up trials, highlighting potential metabolic implications.
Key Takeaways
- ATX-304 raised plasma adiponectin and lowered triglycerides with p<0.01 significance
- MRI-PDFF showed significant decreases in liver fat and visceral adipose tissue
- Resting metabolic rate increased by 8% with minimal weight loss at tested exposure